Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects

Trial Profile

A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Pharmacokinetics
  • Sponsors Eagle Pharmaceuticals
  • Most Recent Events

    • 10 May 2018 According to an Eagle Pharmaceuticals media release, enrollment was completed in February 2018 with study results anticipated in the fall of 2018.
    • 10 May 2018 Status changed from recruiting to active, no longer recruiting, as reported in Eagle Pharmaceuticals media release
    • 26 Feb 2018 According to an Eagle Pharmaceuticals media release, randomization has now been completed ahead of schedule with 600 subjects.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top